Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Aimovig (erenumab) and Ajovy (fremanezumab) are both used to prevent migraines in adults, but they have some differences. Aimovig is a calcitonin gene-related peptide (CGRP) receptor antagonist, while Ajovy is a CGRP receptor blocker. Both work to block the proteins involved with migraine pain. Aimovig is injected once a month, whereas Ajovy offers two dosing options: once a month or once every three months. Both medications are available only as brand-name options and come in prefilled syringes or autoinjectors. Aimovig can cause constipation and high blood pressure, while Ajovy's main side effect is injection-site reactions. Additionally, Aimovig has a specific warning for those with latex allergies, which isn't mentioned for Ajovy. Neither medication is approved for use in children under 18 years old.
Aimovig (erenumab or erenumab-aooe) is a migraine medication called a CGRP antagonist. It helps prevent migraines in adults. Aimovig (erenumab) comes as an autoinjector and prefilled syringe. You inject each dose under the skin in the thigh or stomach once a month. Side effects can include pain, swelling, or redness where you injected the medication.
Summary for CGRP antagonist
Prescription only
Ajovy (fremanezumab or fremanezumab-vfrm) is a type of migraine medication called a calcitonin gene-related peptide (CGRP) antagonist. It's an injection given under the skin to help prevent migraines in adults. It can also help prevent episodic migraines in children ages 6 years and older who weigh at least 99 lbs. This medication is injected once a month or once every 3 months. It's injected using either the prefilled autoinjectors or syringes. Side effects include injection-site reactions like pain, swelling, and redness.